BRAF mutations in Iranian patients with papillary thyroid carcinoma

Asian Pac J Cancer Prev. 2013;14(4):2521-3. doi: 10.7314/apjcp.2013.14.4.2521.

Abstract

Background: Papillary thyroid cancer or papillary thyroid carcinoma (PTC) is the most common thyroid cancer. The fact that it occasionally occurs in women aged 30-40 years old suggests that genetic alterations are involved its genesis. Recently, activator mutations in BRAF gene have been relatively frequently discovered.

Materials and methods: In this study, we tested 63 DNA samples from PTC patients to identify the V600E mutation frequency in the Ahvaz population. DNA was isolated from formalin fixed paraffin-embedded (FFPE) PTC tumor tissues. Genotyping was performed by PCR-RFLP and confirmed by direct DNA sequencing of a subset of PCR products. PCR-RFLP data were reported as genotype frequencies and percentages.

Results: Forty nine out of 63 patients (77.8%) had a mutated heterozygote form while 14 (22.2%) showed normal genotype but none demonstrated a mutant homozygote genotype. The frequency of V600E mutation was significantly high in PTC patients.

Conclusions: These findings support involvement of V600E mutations in PTC occurrence in Iran. Assessment of correlations between BRAF V600E mutations and papillary thyroid cancer progression needs to be performed.

MeSH terms

  • Adult
  • Carcinoma, Papillary / genetics*
  • DNA, Neoplasm / genetics*
  • Female
  • Genotype
  • Humans
  • Iran
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Paraffin Embedding
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Prognosis
  • Proto-Oncogene Proteins B-raf / genetics*
  • Thyroid Neoplasms / genetics*
  • Young Adult

Substances

  • DNA, Neoplasm
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf